JPWO2021108302A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021108302A5 JPWO2021108302A5 JP2022529298A JP2022529298A JPWO2021108302A5 JP WO2021108302 A5 JPWO2021108302 A5 JP WO2021108302A5 JP 2022529298 A JP2022529298 A JP 2022529298A JP 2022529298 A JP2022529298 A JP 2022529298A JP WO2021108302 A5 JPWO2021108302 A5 JP WO2021108302A5
- Authority
- JP
- Japan
- Prior art keywords
- patent document
- alveolar
- emphysema
- document
- life
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Description
肺機能は生まれて30年間で最大になり、その後ゆっくりと低下する。多くの状態は、肺胞の最大数を減らすか、または呼吸不全につながる肺胞喪失の割合を増やす可能性がある。1990年代以来、界面活性剤補充療法および新生児集中治療の進歩により、多くの場合、気管支肺異形成症を有し、ピーク肺胞数が減少する未熟児の生存がますます可能になり、ピーク肺胞数の減少は、この集団が加齢するにつれて未熟児呼吸不全を引き起こす予測が多い1。α-1アンチトリプシン(AAT)欠損症の患者は、おそらく肺胞のピーク数は正常であるが、対立しないタンパク質分解活性は肺胞の喪失を加速し、生まれて40年および50年で肺気腫を引き起こす。喫煙者のサブセットは、肺気腫がこの疾患の主要な要素であるCOPDを発症することになり、これらの患者のサブセットは、禁煙にもかかわらず急速に進行する肺気腫を経験することになる2。これらおよびその他の臨床状況では、進行性の気腔破壊を停止または遅らせる能力により、呼吸生活の質が大幅に向上する可能性がある。したがって、当技術分野における前述の必要性の1つ以上に対処するための組成物および/または方法が必要である。
この出願の発明に関連する先行技術文献情報としては、以下のものがある(国際出願日以降国際段階で引用された文献及び他国に国内移行した際に引用された文献を含む)。
(先行技術文献)
(特許文献)
(特許文献1) 米国特許出願公開第2018/0312477号明細書
(特許文献2) 米国特許出願公開第2015/0140609号明細書
(特許文献3) 米国特許出願公開第2013/0052258号明細書
(特許文献4) 国際公開第2019/140380号
(非特許文献)
(非特許文献1) JOSHI et al."Role for Cela1 in Postnatal Lung Remodeling and Alpha-1 Antitrypsin-Deficient Emphysema," American Journal of Respiratory Cell and Molecular Biology,31 August 2018 (31.08.2018),Vol.59,No.2,Pgs.167-178.entire document
Lung function reaches its maximum during the first 30 years of life and then slowly declines. Many conditions can reduce the maximum number of alveoli or increase the rate of alveolar loss leading to respiratory failure. Since the 1990s, advances in surfactant replacement therapy and neonatal intensive care have made it increasingly possible for premature infants, who often have bronchopulmonary dysplasia and reduced peak alveolar numbers, to survive, and to reduce peak alveolar numbers. A decrease in the number of cysts is often predicted to lead to respiratory failure of prematurity as this population ages. Patients with alpha-1 antitrypsin (AAT) deficiency probably have normal alveolar peak numbers, but unopposed proteolytic activity accelerates alveolar loss and causes emphysema in the fourth and fifth decades of life. cause. A subset of smokers will develop COPD, where emphysema is a major component of the disease, and a subset of these patients will experience rapidly progressive emphysema despite smoking cessation. In these and other clinical situations, the ability to stop or slow progressive airspace destruction could significantly improve the quality of respiratory life. Accordingly, there is a need for compositions and/or methods that address one or more of the aforementioned needs in the art.
Prior art document information related to the invention of this application includes the following (including documents cited in the international phase after the international filing date and documents cited when entering the national phase in another country).
(Prior art document)
(Patent document)
(Patent Document 1) US Patent Application Publication No. 2018/0312477
(Patent Document 2) US Patent Application Publication No. 2015/0140609
(Patent Document 3) US Patent Application Publication No. 2013/0052258
(Patent Document 4) International Publication No. 2019/140380
(Non-patent literature)
(Non-patent Document 1) JOSHI et al. "Role for Cela1 in Postnatal Lung Remodeling and Alpha-1 Antitrypsin-Deficient Emphysema," American Journal of Respiratory Cell and Molecular Biology, 31 August 2018 (31.08.2018), Vol. 59, No. 2, Pgs. 167-178. entire document
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962940302P | 2019-11-26 | 2019-11-26 | |
US62/940,302 | 2019-11-26 | ||
US202063009134P | 2020-04-13 | 2020-04-13 | |
US63/009,134 | 2020-04-13 | ||
PCT/US2020/061774 WO2021108302A1 (en) | 2019-11-26 | 2020-11-23 | Cela-1 inhibition for treatment of lung disease |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023502259A JP2023502259A (en) | 2023-01-23 |
JPWO2021108302A5 true JPWO2021108302A5 (en) | 2023-10-24 |
Family
ID=76129647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022529298A Pending JP2023502259A (en) | 2019-11-26 | 2020-11-23 | CELA-1 inhibition for the treatment of lung disease |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230002510A1 (en) |
EP (1) | EP4065167A4 (en) |
JP (1) | JP2023502259A (en) |
AU (1) | AU2020394374A1 (en) |
IL (1) | IL293238A (en) |
WO (1) | WO2021108302A1 (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY154009A (en) * | 2002-03-13 | 2015-04-30 | Biogen Idec Inc | Anti-alpha v beta 6 antibodies |
US8501449B2 (en) * | 2007-12-04 | 2013-08-06 | Proteon Therapeutics, Inc. | Recombinant elastase proteins and methods of manufacturing and use thereof |
GB0916576D0 (en) * | 2009-09-22 | 2009-10-28 | Malmsten Nils M | Polypeptides and uses thereof |
AU2016245434B2 (en) * | 2015-04-07 | 2020-10-29 | Ela Pharma Ltd | Compositions for treating and/or preventing cell or tissue necrosis specifically targeting Cathepsin C and/or CELA1 and/or CELA3A and/or structurally related enzymes thereto |
WO2019140380A1 (en) * | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
-
2020
- 2020-11-23 IL IL293238A patent/IL293238A/en unknown
- 2020-11-23 EP EP20894493.4A patent/EP4065167A4/en active Pending
- 2020-11-23 AU AU2020394374A patent/AU2020394374A1/en active Pending
- 2020-11-23 WO PCT/US2020/061774 patent/WO2021108302A1/en unknown
- 2020-11-23 US US17/778,188 patent/US20230002510A1/en active Pending
- 2020-11-23 JP JP2022529298A patent/JP2023502259A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Koblizek et al. | Chronic Obstructive Pulmonary Disease: official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care | |
Hilgendorff et al. | Bronchopulmonary dysplasia early changes leading to long-term consequences | |
Mak | Pathogenesis of COPD. Part II. Oxidative-antioxidative imbalance [State of the Art Series. Chronic obstructive pulmonary disease in high-and low-income countries. Edited by G. Marks and M. Chan-Yeung. Number 3 in the series] | |
WO2005086915A3 (en) | Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor | |
DK1718336T3 (en) | New combination of anticholinergic and beta-mimetics for the treatment of respiratory diseases | |
SE0200356D0 (en) | Novel use | |
JP2016500111A5 (en) | ||
JP2012500091A5 (en) | ||
NO20082000L (en) | Pyrimidinamide Compounds as PGDS Inhibitors | |
Pilecki et al. | Surfactant protein D deficiency aggravates cigarette smoke-induced lung inflammation by upregulation of ceramide synthesis | |
WO2004011613A3 (en) | Composition & methods for treatment and screening | |
Aggarwal et al. | Oxidative, inflammatory, genetic, and epigenetic biomarkers associated with chronic obstructive pulmonary disorder | |
JPWO2021108302A5 (en) | ||
NO20061513L (en) | Condensed ring compound and its use | |
Ogilvie et al. | Patterns of disturbed lung function in patients with emphysematous bullae | |
George | Course and prognosis of chronic obstructive pulmonary disease | |
BR112022014114A2 (en) | COMPOSITIONS TO MANAGE CHRONIC OBSTRUCTIVE PULMONARY DISEASE | |
Girón-Martínez et al. | Proliferative activity of liver growth factor is associated with an improvement of cigarette smoke-induced emphysema in mice | |
Echternach et al. | Does isolated expiratory vocal cord dysfunction exist? | |
DE60141083D1 (en) | LEPTIN FOR THE TREATMENT OF RESPIRATORY DISTRESS SYNDROME AND REDUCED LUNG SURFACTANT PRODUCTION | |
Verma et al. | Therapeutic role of Shwasa Kuthar rasa in the management of Tamaka Shwasa (bronchial asthma): A single group randomized clinical trial | |
MARUOKA et al. | The Influence of the Heat-not-burn Cigarettes on Alveolus and Cytokine─ The Analysis of Chronic Obstructive Pulmonary Disease (COPD) and Skeletal Muscle Atrophy Model Mice─ | |
KR102033280B1 (en) | Method for predicting therapeutic response of recurrent wheezing | |
IS2037B (en) | Replaces beta-diketones and their use | |
Kadri et al. | Saliva of Tobacco Smokers a Profile of C3, IgA, Amylase and Total Protein |